医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fast Growing Australian MedTech Startup RxMx Partners with InterSystems to Enhance the Safe Use of New Medicines

2018年12月10日 PM11:00
このエントリーをはてなブックマークに追加


 

SYDNEY

InterSystems, a global leader in information technology platforms for health, business and government applications, today announced that fast growing Australian medical technology company RxMx will expand its partnership with InterSystems to increase its agility in developing solutions that enhance the safe use of medicines.

Using the InterSystems database platform, RxMx has built and deployed an automated patient monitoring system for complex medicines that require ongoing laboratory testing for potential adverse effects. The system uses real-time algorithms to detect at-risk test results and notifies or provides reminders to doctors, nurses and patients via emails, texts and mobile apps.

RxMx has been recognized in the Deloitte Technology Fast 50 2018 and Australian Financial Review Fast Starters 2018 lists for its rapid growth rate, at 193 percent year over year.

The company will migrate to InterSystems IRIS for Health™, the first and only data platform engineered specifically for healthcare, to adapt to an extremely rapidly changing environment, according to RxMx Co-founder, Associate Professor Sean Riminton.

“It is an incredibly fast-moving field. We are fortunate that InterSystems is willing to innovate with us to keep ahead,” said Dr Riminton. “As RxMx goes from strength to strength, the volume of data that we collect, analyse and report increases dramatically. We therefore need adaptability from our core technology vendor to be able to rapidly recruit new sources of information into our network.”

“We are working towards continuous deployment and we know that InterSystems IRIS for Health can facilitate that with support for container technology,” said Ben Rhodes, Software Development Manager for RxMx, adding that the company’s interoperability requirements are also expanding. “As we scale up to support multiple new medications in markets such as the U.S. and Europe, we may have to integrate with 10 or more different laboratories and vendors, each providing real-time data feeds to a single RxMx platform.”

Scalability, performance and the responsiveness of InterSystems are critically important to RxMx, said Rhodes. “With InterSystems, RxMx never experience issues with the database. The system just runs and the performance will scale to whatever we need. It is important to know that InterSystems is there to make it work, and will always send the right people to help us should we need them.”

InterSystems IRIS for Health extends the InterSystems IRIS Data Platform, which combines transaction processing and analytics with embedded interoperability to offer a fast development platform for building mission-critical applications at scale. InterSystems IRIS for Health adds healthcare-specific capabilities for real-time connected care solutions, including a framework for rapid development of solutions using Health Level Seven (HL7) Fast Healthcare Interoperability Resources (FHIR).

“With clinically proven technology solutions that improve patient safety and which are deployed around the world, RxMx has achieved an enormous amount in a very short time,” said Luciano Brustia, Country Manager, Australia and Greater China for InterSystems. “With InterSystems IRIS for Health, we look forward to partnering with RxMx to meet whatever technology challenges lie ahead.”

About InterSystems
InterSystems is the engine behind the world’s most important applications. In healthcare, finance, government, and other sectors where lives and livelihoods are at stake, InterSystems is the power behind what matters™. Founded in 1978, InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, visit InterSystems.com.

About RxMx
RxMx offers an innovative suite of medical solutions that enhance the safe use of medicines, optimising patient safety and delivering real-world efficiency in busy clinical settings through systems integrations and innovations. For further details see rxmxcorp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20181210005083/en/

CONTACT

InterSystems PR Contact:
Chris Bowes
Bowes
Communications
chris.bowes@bowespr.com
T:
+61 2 9387 2332

RxMx Contact:
Jasper McDonald Blair
RxMx Corporation
jasper.blair@rxmxcorp.com
T:
+61 488 022 530

同じカテゴリーの記事 

  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護
  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携